Silo Pharma Stock Jumps 43% After Patent

Silo Pharma Inc shares jumped ~43.5% after the European Patent Office signaled intent to grant a stress‑prevention therapy patent.
The patent, titled “Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covers 5‑HT4 agonist methods to prevent stress‑induced fear and depressive behavior.
The technology is licensed from Columbia University, and Silo Pharma is pursuing Unitary Patent protection and national validations for broad European coverage.
Silo Pharma emphasizes developing novel formulations and drug‑delivery systems for both traditional therapeutics and psychedelic treatments targeting stress resilience.